NO970282D0 - Adénovirus omfattende et gen som koder for glutationperoksydase - Google Patents

Adénovirus omfattende et gen som koder for glutationperoksydase

Info

Publication number
NO970282D0
NO970282D0 NO970282A NO970282A NO970282D0 NO 970282 D0 NO970282 D0 NO 970282D0 NO 970282 A NO970282 A NO 970282A NO 970282 A NO970282 A NO 970282A NO 970282 D0 NO970282 D0 NO 970282D0
Authority
NO
Norway
Prior art keywords
adenovirus
glutathione peroxidase
gene encoding
encoding glutathione
relates
Prior art date
Application number
NO970282A
Other languages
English (en)
Norwegian (no)
Other versions
NO970282L (no
Inventor
Martine Barkats
Jacques Mallet
Frederic Revah
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO970282L publication Critical patent/NO970282L/no
Publication of NO970282D0 publication Critical patent/NO970282D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
NO970282A 1994-08-12 1997-01-22 Adénovirus omfattende et gen som koder for glutationperoksydase NO970282D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9409982A FR2723588B1 (fr) 1994-08-12 1994-08-12 Adenovirus comprenant un gene codant pour la glutathion peroxydase
PCT/FR1995/001002 WO1996005320A1 (fr) 1994-08-12 1995-07-26 Adenovirus comprenant un gene codant pour la glutathion peroxydase

Publications (2)

Publication Number Publication Date
NO970282L NO970282L (no) 1997-01-22
NO970282D0 true NO970282D0 (no) 1997-01-22

Family

ID=9466290

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970282A NO970282D0 (no) 1994-08-12 1997-01-22 Adénovirus omfattende et gen som koder for glutationperoksydase

Country Status (14)

Country Link
US (2) US20010029249A1 (sv)
EP (1) EP0775213B1 (sv)
JP (1) JPH10504193A (sv)
AT (1) ATE293700T1 (sv)
AU (1) AU710727B2 (sv)
CA (1) CA2197235C (sv)
DE (1) DE69534165T2 (sv)
FI (1) FI970579A (sv)
FR (1) FR2723588B1 (sv)
IL (1) IL114904A0 (sv)
MX (1) MX9700851A (sv)
NO (1) NO970282D0 (sv)
WO (1) WO1996005320A1 (sv)
ZA (1) ZA956678B (sv)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6200799B1 (en) * 1997-06-03 2001-03-13 University Of Lausanne Somatic gene therapy to suppress secondary cataract formation following eye surgery
AU9363798A (en) 1997-11-06 1999-05-31 Chiron S.P.A. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
ES2304065T3 (es) 1998-05-01 2008-09-01 Novartis Vaccines And Diagnostics, Inc. Antigenos y composiciones de neisseria meningitidis.
NZ581940A (en) 1999-04-30 2011-07-29 Novartis Vaccines & Diagnostic Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
DK2289545T3 (en) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Supplemented OMV vaccine against meningococcus
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
EP1474158B1 (en) * 2001-12-18 2009-10-14 Brassica Foundation for Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by compounds which elevate intracellular levels of glutathione or phase ii detoxification enzymes
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
KR102393885B1 (ko) * 2014-06-27 2022-05-02 앤지오크린 바이오사이언스 인코포레이티드 아데노바이러스 e4orf1을 발현하는 신경 세포 및 그 제조 방법과 용도
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007541A1 (en) * 1987-04-01 1988-10-06 Chiron Corporation Polynucleotide construct encoding a polypeptide substantially similar to human glutathione peroxidase
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
JPH0327289A (ja) 1989-06-22 1991-02-05 Toyo Jozo Co Ltd 新規な血漿型グルタチオン・パーオキシダーゼ遺伝子およびその用途
AU3969993A (en) * 1992-04-01 1993-11-08 Cornell Research Foundation Inc. Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
AU7019494A (en) 1993-05-20 1994-12-20 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system

Also Published As

Publication number Publication date
JPH10504193A (ja) 1998-04-28
FI970579A0 (sv) 1997-02-11
WO1996005320A1 (fr) 1996-02-22
ATE293700T1 (de) 2005-05-15
DE69534165T2 (de) 2006-03-09
AU710727B2 (en) 1999-09-30
FI970579A (sv) 1997-02-11
EP0775213A1 (fr) 1997-05-28
DE69534165D1 (de) 2005-05-25
US20010029249A1 (en) 2001-10-11
EP0775213B1 (fr) 2005-04-20
CA2197235C (fr) 2010-07-20
CA2197235A1 (fr) 1996-02-22
NO970282L (no) 1997-01-22
US20040175363A1 (en) 2004-09-09
AU3082695A (en) 1996-03-07
IL114904A0 (en) 1995-12-08
MX9700851A (es) 1997-04-30
ZA956678B (en) 1996-03-20
FR2723588A1 (fr) 1996-02-16
US7241591B2 (en) 2007-07-10
FR2723588B1 (fr) 1996-09-20

Similar Documents

Publication Publication Date Title
NO970282L (no) Adénovirus omfattende et gen som koder for glutationperoksydase
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
HUP0300246A2 (en) Delivery system
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
BG104780A (en) Inhibitors of phospholipase enzymes
ATE380037T1 (de) Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie
ES2042693T3 (es) Formulaciones proteinicas de plasma y recombinantes en medios de baja potencia ionica.
MX9606327A (es) Adenovirus que comprende un gen que codifica para un superoxido dismutasa.
DK0994710T4 (da) Farmaceutiske præparater til oral indgivelse omfattende en benzylhydrylpiperazin og en cyclodextrin
IL138665A0 (en) Peptide factor
DE69905170T2 (de) Thiazolopyrimidinderivate
ZA933598B (en) New pharmaceutical used of krill enyzmes
DK0495918T3 (da) Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
NO910982L (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
BR9911917A (pt) Composições compreendendo análogos de gaba e cafeìna
NO981019L (no) Deodoriserende preparater inneholdende kationiske biopolymerer, aluminiumklorhydrat og esteraseinhibitorer
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
ATE305517T1 (de) Neurotrypsin
ATE28188T1 (de) Antikonvulsive mittel.
BR9802803A (pt) ação e composições farmacêuticas contendo os mesmos.
ATE223427T1 (de) Modifizierte kojibioside analoge
MX9706569A (es) Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application